OnCusp Therapeutics is a technology company.
OnCusp Therapeutics has raised $100.0M across 1 funding round.
OnCusp Therapeutics has raised $100.0M in total across 1 funding round.
OnCusp Therapeutics has raised $100.0M in total across 1 funding round.
OnCusp Therapeutics's investors include F-Prime Capital Partners, Novo Ventures, OrbiMed.
OnCusp Therapeutics is a clinical-stage biopharmaceutical company developing innovative oncology treatments, particularly antibody-drug conjugates (ADCs) like its lead candidate CUSP06, a Cadherin-6 (CDH6)-targeted ADC for platinum-resistant ovarian cancer and other solid tumors.[1][2][3] It serves cancer patients worldwide by transforming cutting-edge preclinical assets into clinically validated therapies, addressing unmet needs in hard-to-treat cancers through a portfolio backed by $139 million in Seed and Series A funding, including an oversubscribed $100 million Series A.[1][6] The company has achieved key milestones like FDA IND clearance, first patient dosing in a Phase 1 trial (NCT06234423), and Fast Track Designation for CUSP06 in February 2025, demonstrating strong growth momentum.[1][3][6]
Headquartered primarily in Princeton, New Jersey (with earlier mentions in New York City), OnCusp leverages a veteran team experienced in biotech startups, clinical programs, and global partnerships to accelerate globally competitive oncology assets.[1][2][3]
OnCusp Therapeutics was co-founded in early 2021 by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, each bringing deep expertise in biotech entrepreneurship, clinical development, and business strategy.[1][2][3] Dr. Yuan, a key figure, built the initial team, developed the asset portfolio, and secured $139 million from leading investors like F-Prime Capital (initial investment in 2023).[1][2][6] The idea emerged from recognizing opportunities to in-license and advance promising preclinical oncology innovations, such as obtaining exclusive global rights (outside China) to CUSP06 from Multitude Therapeutics in 2022.[3] Pivotal early traction included FDA clearance for CUSP06's Phase 1 trial, showcasing anti-tumor activity at the AACR 2023 meeting, and transitioning to clinical-stage status with first patient dosing.[1][3][6]
OnCusp rides the surging wave of ADC therapeutics in oncology, a trend fueled by successes like Enhertu and Trodelvy, where targeted payloads improve efficacy in solid tumors amid rising cancer incidence.[1][3] Timing is ideal post-2021 founding, aligning with FDA's support for rapid oncology development (e.g., Fast Track for CUSP06) and investor appetite for clinical-stage biotechs, as seen in its $139M raise.[1][3][6] Market forces like demand for therapies in platinum-resistant ovarian cancer—an underserved area with limited options—favor OnCusp, while its global rights model taps China's innovation pipeline for Western markets.[3] It influences the ecosystem by validating cross-border asset transfers and accelerating "second-in-class" ADCs with improved profiles.[1][3]
OnCusp is poised for Phase 1 data readouts from CUSP06-1001, potential expansion to other CDH6-expressing tumors, and portfolio growth via its translational platform.[1][3] Rising ADC momentum, FDA incentives, and biotech funding recovery will shape its path, possibly leading to Phase 2 trials or partnerships by 2026.[3][6] Its influence may evolve from agile innovator to major player in ovarian cancer, delivering on its mission to transform preclinical hope into global treatments—echoing its founding commitment to cancer patients worldwide.[1][4]
OnCusp Therapeutics has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $100.0M Series A | F-Prime Capital Partners, Novo Ventures, OrbiMed |